Whole-exome sequencing of alpha-fetoprotein producing gastric carcinoma reveals genomic profile and therapeutic targets
Jun Lu,Yongfeng Ding,Yanyan Chen,Junjie Jiang,Yiran Chen,Yingying Huang,Mengjie Wu,Chengzhi Li,Mei Kong,Wenyi Zhao,Haohao Wang,Jing Zhang,Zhongqi Li,Yimin Lu,Xiongfei Yu,Ketao Jin,Donghui Zhou,Tianhua Zhou,Fei Teng,Haibin Zhang,Zhan Zhou,Haiyong Wang,Lisong Teng
DOI: https://doi.org/10.1038/s41467-021-24170-0
IF: 16.6
2021-06-24
Nature Communications
Abstract:Abstract Alpha-fetoprotein producing gastric carcinoma (AFPGC) is a rare and aggressive subtype of gastric cancer. However, little is known about the genomic features of this disease. We perform whole-exome sequencing analysis of AFPGC, and identify 34 significantly mutated genes. Somatic copy number alterations analysis reveals several significant focal amplifications (e.g. 19q12, 17q12) and focal deletions (e.g. 1p36.11, 9p21.3), and some of these negatively affect the patient prognosis. Comparative analyses reveal that AFPGC has distinct genomic features from gastric cancer of The Cancer Genome Atlas as well as four molecular subtypes. Several frequently altered genes with potential as therapeutic targets are identified in AFPGC. Further analysis reveals that AFPGC with amplification of CCNE1 at 19q12 and/or ERBB2 at 17q12 show poorer survival and more aggressive. Subsequently, based on our established patient-derived xenograft models for AFPGC, translational research is performed and the therapeutic value of targeting CCNE1 and ERBB2 is validated. In this work, we provide an understanding of genomic characteristics of AFPGC and propose a platform to explore and validate the genome-guided personalized treatment for this disease.
multidisciplinary sciences